1
|
Jahnke W, Bold G, Marzinzik AL, Ofner S, Pellé X, Cotesta S, Bourgier E, Lehmann S, Henry C, Hemmig R, Stauffer F, Hartwieg JCD, Green JR, Rondeau JM. A General Strategy for Targeting Drugs to Bone. Angew Chem Int Ed Engl 2015; 54:14575-9. [PMID: 26457482 DOI: 10.1002/anie.201507064] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Indexed: 11/08/2022]
Abstract
Targeting drugs to their desired site of action can increase their safety and efficacy. Bisphosphonates are prototypical examples of drugs targeted to bone. However, bisphosphonate bone affinity is often considered too strong and cannot be significantly modulated without losing activity on the enzymatic target, farnesyl pyrophosphate synthase (FPPS). Furthermore, bisphosphonate bone affinity comes at the expense of very low and variable oral bioavailability. FPPS inhibitors were developed with a monophosphonate as a bone-affinity tag that confers moderate affinity to bone, which can furthermore be tuned to the desired level, and the relationship between structure and bone affinity was evaluated by using an NMR-based bone-binding assay. The concept of targeting drugs to bone with moderate affinity, while retaining oral bioavailability, has broad application to a variety of other bone-targeted drugs.
Collapse
Affiliation(s)
- Wolfgang Jahnke
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland).
| | - Guido Bold
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Andreas L Marzinzik
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Silvio Ofner
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Xavier Pellé
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Simona Cotesta
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Emmanuelle Bourgier
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Sylvie Lehmann
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Chrystelle Henry
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - René Hemmig
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Frédéric Stauffer
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - J Constanze D Hartwieg
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Jonathan R Green
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| | - Jean-Michel Rondeau
- Novartis Institutes for BioMedical Research, Center for Proteomic Chemistry and Oncology Research, 4002 Basel (Switzerland)
| |
Collapse
|
2
|
Jahnke W, Bold G, Marzinzik AL, Ofner S, Pellé X, Cotesta S, Bourgier E, Lehmann S, Henry C, Hemmig R, Stauffer F, Hartwieg JCD, Green JR, Rondeau JM. Gezielte Anreicherung von Wirkstoffen am Knochen am Beispiel von allosterischen FPPS-Inhibitoren. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201507064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
3
|
Lombès T, Moumné R, Larue V, Prost E, Catala M, Lecourt T, Dardel F, Micouin L, Tisné C. Investigation of RNA-Ligand Interactions by 19F NMR Spectroscopy Using Fluorinated Probes. Angew Chem Int Ed Engl 2012; 51:9530-4. [DOI: 10.1002/anie.201204083] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2012] [Indexed: 01/08/2023]
|
4
|
Lombès T, Moumné R, Larue V, Prost E, Catala M, Lecourt T, Dardel F, Micouin L, Tisné C. Investigation of RNA-Ligand Interactions by 19F NMR Spectroscopy Using Fluorinated Probes. Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201204083] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
5
|
Jahnke W, Henry C. An in vitro Assay to Measure Targeted Drug Delivery to Bone Mineral. ChemMedChem 2010; 5:770-6. [DOI: 10.1002/cmdc.201000016] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|